Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials

BACKGROUND: There is a necessity for an optimal COVID-19 vaccination strategy for vulnerable population groups, including people with autoimmune inflammatory arthritis on immunosuppressants such as methotrexate, which inhibit vaccine-induced immunity against SARS-CoV-2. Thus, we aimed to assess the...

Descripción completa

Detalles Bibliográficos
Autores principales: Skaria, Teny Grace, Sreeprakash, Anu, Umesh, Rashwith, Joseph, Sneha, Mohan, Manju, Ahmed, Sakir, Mehta, Pankti, Oommen, Seena Elsa, Benny, Jannet, Paulose, Anagha, Paul, Aby, George, Justin, Sukumaran, Aswathy, Babu, Sageer S, Navas, Safna, Vijayan, Anuroopa, Joseph, Sanjana, Nalianda, Kaveri K, Narayanan, Krishnan, Shenoy, Padmanabha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612848/
https://www.ncbi.nlm.nih.gov/pubmed/36320825
http://dx.doi.org/10.1016/S2665-9913(22)00228-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612848/
https://www.ncbi.nlm.nih.gov/pubmed/36320825
http://dx.doi.org/10.1016/S2665-9913(22)00228-4

Ejemplares similares